EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Stepping Up With Immune Checkpoint Blockade: More Combinations and Fewer Contraindications

Justine V Cohen iD, Adam Adika, Matthew Zibelman, Stuart J Gallagher, Karam Khaddour, Ann W Silk, Matteo S Carlino

American Society of Clinical Oncology Educational Book · 2026-06 · 46 (3)

DOI: 10.1200/edbk-26-520792 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2026-06. Verfasst von Justine V Cohen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms. Die Arbeit nennt 74 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) have transformed the treatment of a broad range of malignancies over the past decade. As the scope of indications and the clinical experience expands, oncologists are increasingly confronted with complex scenarios. This chapter addresses three of the most clinically challenging frontiers in ICI use: the safe and effective application of checkpoint blockade in patients with preexisting autoimmune disease, the evolving toxicity landscape of ICI-based combination regimens including chemotherapy + immune checkpoint inhibition, immune checkpoint inhibition + tyrosine kinase inhibitor, and immune checkpoint inhibition + antibody-drug conjugate, and the emerging evidence supporting ICI in solid organ transplant recipients with advanced malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsNeoplasmsHumansTreatment OutcomeAntineoplastic Combined Chemotherapy Protocols

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.
  • Fox Chase Cancer Center, Philadelphia, PA.
  • Westmead and Blacktown Hospitals, Sydney Australia.
  • Westmead and Blacktown Hospitals, The Melanoma Institute Australia and the University of Sydney, Sydney Australia.

ORCID-Profile: Justine V Cohen

Zitieren

APA

Cohen, J. V., Adika, A., Zibelman, M., Gallagher, S. J., Khaddour, K., Silk, A. W., & Carlino, M. S. (2026). Stepping Up With Immune Checkpoint Blockade: More Combinations and Fewer Contraindications. American Society of Clinical Oncology Educational Book, 46(3). https://doi.org/10.1200/edbk-26-520792

Vancouver

Cohen JV, Adika A, Zibelman M, Gallagher SJ, Khaddour K, Silk AW, et al. Stepping Up With Immune Checkpoint Blockade: More Combinations and Fewer Contraindications. American Society of Clinical Oncology Educational Book. 2026;46(3). doi:10.1200/edbk-26-520792

BibTeX
@article{Cohen2026,
  author = {Cohen, Justine V and Adika, Adam and Zibelman, Matthew and Gallagher, Stuart J and Khaddour, Karam and Silk, Ann W and Carlino, Matteo S},
  title = {Stepping Up With Immune Checkpoint Blockade: More Combinations and Fewer Contraindications},
  journal = {American Society of Clinical Oncology Educational Book},
  year = {2026},
  volume = {46},
  number = {3},
  doi = {10.1200/edbk-26-520792}
}
Kostenlos starten →